|
|
Latest Brain and CNS Cancers - General News
Avastin® Approved for Progressive Glioblastoma (5/7/2009)
The U.S. Food and Drug Administration (FDA) has expanded the approval of the drug Avastin® (bevacizumab) to include treatment of glioblastoma that has progressed following prior therapy. Avastin was already approved for selected patients with advanced breast cancer, colorectal cancer, or non–small cell lung cancer.
Temodar® plus Radiation Improves Survival for Brain Cancer (3/23/2009)
Radiation therapy plus chemotherapy with Temodar® (temozolomide) improves survival in patients with glioblastoma; almost 10% of patients treated with the combination therapy were alive after five years, compared with 2% of patients treated with radiation alone. The results of this study were published in the Lancet Oncology.
Tarceva® and Temodar® plus Radiation Improves Survival in Glioblastoma Multiforme (2/11/2009)
The addition of Tarceva® (erlotinib) and Temodar® (temozolomide) during and after radiation therapy improves survival in patients with newly diagnosed glioblastoma multiforme (GBM) and gliosarcoma, according to the results of a study published in the Journal of Clinical Oncology.
Treatment Guidelines for Patients with Newly Diagnosed Glioblastoma Multiforme (10/1/2008)
For the first time ever, the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors has issued treatment guidelines for patients with newly diagnosed glioblastoma multiforme. The guidelines were published in the September issue of the Journal of Neuro-Oncology.
Cell Phone Use Does Not Increase Risk of Developing Meningioma Brain Cancer (9/26/2008)
Researchers from Finland, Denmark, the United Kingdom, Sweden, and Norway have reported that long-term data do not indicate an association between the use of cell phones and an increased risk of meningioma. The details of this study appeared in an early online publication in the International Journal of Epidemiology.
|
|
